LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright

H.C. Wainwright increased its price target for LENZ Therapeutics Inc. (NASDAQ:LENZ) to $56.00 from $48.00, maintaining a Buy rating, following FDA approval of VIZZ, its novel aceclidine-based topical therapy for presbyopia. VIZZ is positioned as a superior second-generation treatment, offering improved efficacy and durability compared to existing options, with commercial samples expected by October 2025 and a broader launch in Q4 2025. LENZ, identified as a top H.C. Wainwright pick for H2 2025, demonstrates strong financial health with a 20.54 current ratio and $209.6 million in cash, supporting its strategic market entry.

Analysis

LENZ Therapeutics (NASDAQ:LENZ) has received a significant catalyst with the FDA approval of VIZZ, its novel aceclidine-based eye drop for presbyopia. This regulatory milestone prompted H.C. Wainwright to raise its price target to $56.00 from $48.00 while maintaining a Buy rating, identifying the company as a top pick for the second half of 2025. The drug is strategically positioned as a second-generation treatment, aiming to overcome the reported efficacy, durability, and safety shortcomings of first-generation competitors like AbbVie's VUITY. VIZZ's unique mechanism, targeting the iris sphincter muscle, is expected to offer superior, all-day performance. Financially, LENZ appears well-prepared for commercialization, holding a cash reserve of $209.6 million, which management anticipates is sufficient to fund operations to post-launch profitability, and a robust current ratio of 20.54. The company has proactively built an 88-member sales force, with a clear go-to-market strategy involving sample distribution by October 2025 and a full commercial launch in the fourth quarter of 2025.

Key Decisions for Investors

• With the primary regulatory hurdle for VIZZ now cleared, the investment thesis shifts from clinical risk to commercial execution risk, warranting close attention to the launch performance in late 2025.
• Investors should monitor the initial market uptake and physician feedback post-launch to validate VIZZ's competitive advantages over AbbVie's VUITY, which will be critical for achieving the $56 price target.
• While the company's liquidity appears strong with $209.6 million in cash, tracking the quarterly cash burn rate through the commercial launch phase is essential to ensure it aligns with management's projection of reaching positive cash flow.
• The stock's nearly 25% appreciation over the past year reflects growing optimism, but future performance will be highly dependent on the sales ramp-up and successfully capturing market share in the presbyopia space.